Highlights: Diabetes patients belong to higher risk population for COVID-19 infection and associated complications, necessitating optimal glycemic regulation. 1 Some antidiabetic agents have shown potential effect against COVID-19 along with glycemic normalization. 1 Dipeptidyl peptidase-4 (DPP-4) inhibitors exert anti-inflammatory effects, which could be beneficial in patients exposed to cytokine storms due to COVID-19. 2 This interactive article elucidates the potential therapeutic action of DPP-4 inhibitors in COVID-19 disease .
Antidiabetic agents against SARS-CoV-2 Infection Patients with comorbidities are observed to be at higher risk of COVID-19. Diabetes represents the one of the most important comorbidities related to the severity of COVID-19 infection and possess a higher risk of COVID-19 related serious complications. Given the crucial link between COVID-19 and diabetes, it…
